40 related articles for article (PubMed ID: 10417342)
21. Prospective on ovarian cancer: why prevent?
Hoskins WJ
J Cell Biochem Suppl; 1995; 23():189-99. PubMed ID: 8747396
[TBL] [Abstract][Full Text] [Related]
22. The plasminogen-activation system in ovarian tumors.
Pujade-Lauraine E; Lu H; Mirshahi S; Soria J; Soria C; Bernadou A; Kruithof EK; Lijnen HR; Burtin P
Int J Cancer; 1993 Aug; 55(1):27-31. PubMed ID: 8344749
[TBL] [Abstract][Full Text] [Related]
23. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium.
Young TN; Rodriguez GC; Moser TL; Bast RC; Pizzo SV; Stack MS
Am J Obstet Gynecol; 1994 May; 170(5 Pt 1):1285-96. PubMed ID: 8178854
[TBL] [Abstract][Full Text] [Related]
24. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma.
Moser TL; Young TN; Rodriguez GC; Pizzo SV; Bast RC; Stack MS
Int J Cancer; 1994 Feb; 56(4):552-9. PubMed ID: 8112891
[TBL] [Abstract][Full Text] [Related]
25. Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts.
De Petro G; Copeta A; Barlati S
Exp Cell Res; 1994 Jul; 213(1):286-94. PubMed ID: 8020601
[TBL] [Abstract][Full Text] [Related]
26. Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation.
Kazama Y; Hamamoto T; Foster DC; Kisiel W
J Biol Chem; 1995 Jan; 270(1):66-72. PubMed ID: 7814421
[TBL] [Abstract][Full Text] [Related]
27. An examination of the inhibitory mechanism of serpins by analysing the interaction of trypsin and chymotrypsin with alpha 2-antiplasmin.
Enghild JJ; Valnickova Z; Thøgersen IB; Pizzo SV; Salvesen G
Biochem J; 1993 May; 291 ( Pt 3)(Pt 3):933-8. PubMed ID: 7683878
[TBL] [Abstract][Full Text] [Related]
28. Reactivity of a monoclonal antibody with human ovarian carcinoma.
Bast RC; Feeney M; Lazarus H; Nadler LM; Colvin RB; Knapp RC
J Clin Invest; 1981 Nov; 68(5):1331-7. PubMed ID: 7028788
[TBL] [Abstract][Full Text] [Related]
29. Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.
Kirchheimer JC; Wojta J; Christ G; Hienert G; Binder BR
Carcinogenesis; 1988 Nov; 9(11):2121-3. PubMed ID: 3180347
[TBL] [Abstract][Full Text] [Related]
30. Proliferation of a human epidermal tumor cell line stimulated by urokinase.
Kirchheimer JC; Wojta J; Christ G; Binder BR
FASEB J; 1987 Aug; 1(2):125-8. PubMed ID: 3038646
[TBL] [Abstract][Full Text] [Related]
31. Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.
Lijnen HR; Van Hoef B; Collen D
Eur J Biochem; 1987 Dec; 169(2):359-64. PubMed ID: 2961562
[TBL] [Abstract][Full Text] [Related]
32. Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2.
Koivunen E; Itkonen O; Halila H; Stenman UH
Cancer Res; 1990 Apr; 50(8):2375-8. PubMed ID: 2180568
[TBL] [Abstract][Full Text] [Related]
33. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells.
Rabbani SA; Desjardins J; Bell AW; Banville D; Mazar A; Henkin J; Goltzman D
Biochem Biophys Res Commun; 1990 Dec; 173(3):1058-64. PubMed ID: 2125213
[TBL] [Abstract][Full Text] [Related]
34. The matrix metalloproteinase pump-1 catalyzes formation of low molecular weight (pro)urokinase in cultures of normal human kidney cells.
Marcotte PA; Kozan IM; Dorwin SA; Ryan JM
J Biol Chem; 1992 Jul; 267(20):13803-6. PubMed ID: 1629180
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B.
Kobayashi H; Ohi H; Sugimura M; Shinohara H; Fujii T; Terao T
Cancer Res; 1992 Jul; 52(13):3610-4. PubMed ID: 1617632
[TBL] [Abstract][Full Text] [Related]
36. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
Rabbani SA; Mazar AP; Bernier SM; Haq M; Bolivar I; Henkin J; Goltzman D
J Biol Chem; 1992 Jul; 267(20):14151-6. PubMed ID: 1321137
[TBL] [Abstract][Full Text] [Related]
37. The two human trypsinogens. Inhibition spectra of the two human trypsins derived from their purified zymogens.
Figarella C; Negri GA; Guy O
Eur J Biochem; 1975 May; 53(2):457-63. PubMed ID: 1079768
[TBL] [Abstract][Full Text] [Related]
38. Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity.
Shi Z; Stack MS
Biochem J; 2007 Oct; 407(2):153-9. PubMed ID: 17880283
[TBL] [Abstract][Full Text] [Related]
39. Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment.
Fishman DA; Kearns A; Larsh S; Enghild JJ; Stack MS
Biochem J; 1999 Aug; 341 ( Pt 3)(Pt 3):765-9. PubMed ID: 10417342
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
